InvestorsHub Logo
Followers 88
Posts 8196
Boards Moderated 0
Alias Born 06/17/2013

Re: None

Thursday, 06/25/2020 5:08:31 PM

Thursday, June 25, 2020 5:08:31 PM

Post# of 64370
WCG Center Watch
https://www.centerwatch.com/clinical-trials/listings/245747/covid19-quadramunetm-prevention-covid-19/?&radius=50

The trusted Source For Clinical Trials Information

Last updated on June 2020

QuadraMune(TM) for Prevention of COVID-19

Brief description of study

QuadraMune(TM) is a nutritional supplement which has previously been demonstrated to possess antiinflammatory and immune modulatory activity based on in vitro and pilot in vivo studies. The current clinical trial aims to assess in a 500 volunteer trial the efficacy of QuadraMune(TM) in reducing infection in individuals at high risk of COVID-19.

Detailed Study Description

QuadraMune(TM) is composed of 4 natural ingredients.

Pterostilbene is an analogue of resveratrol, and has been shown to possess antiinflammatory activity. Additionally, this compound suppresses macrophage activation while enhancing NK activity.

Epigallocatechin gallate (EGCG) is one of the active ingredients in green tea and has been shown to act as an activator of T cells, and a suppressor of neutrophil mediated inflammation.

Sulforaphane is derived from broccoli and studies have shown that it protects lungs from inflammatory pathology.

Thymoquinone, which is chemically related to hydroxychloroquine, possessing antiviral effects and increases NK activity.

QuadraMune is a combination of these ingredients and is believed to possess superior in vitro and in vivo therapeutic properties as compared to when the ingredients are administered individually.

The study aims to assess preventative effects of QuadraMune(TM) administration for 12 weeks.

Clinical Study Identifier: NCT04421391
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TSOI News